155 related articles for article (PubMed ID: 11142490)
1. A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levels.
Benboubker L; Valat C; Linassier C; Cartron G; Delain M; Bout M; Fetissof F; Lefranq T; Lamagnere JP; Colombat P
Ann Oncol; 2000 Nov; 11(11):1485-91. PubMed ID: 11142490
[TBL] [Abstract][Full Text] [Related]
2. An improved prognostic parameter for non-Hodgkin's lymphoma based on the combination of three serum tumor markers.
Gui W; Wang T; Wang J; Wang L; He J; Yang B; Zhao Z; Zhang H; Zhang Q
Int J Biol Markers; 2008; 23(4):207-13. PubMed ID: 19199267
[TBL] [Abstract][Full Text] [Related]
3. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma.
Zidan J; Hussein O; Basher W; Zohar S
Oncologist; 2004; 9(4):417-21. PubMed ID: 15266095
[TBL] [Abstract][Full Text] [Related]
4. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity.
Lazzarino M; Orlandi E; Klersy C; Astori C; Brusamolino E; Corso A; Bellio L; Gargantini L; Morra E; Bernasconi C
Cancer; 1998 Feb; 82(3):576-82. PubMed ID: 9452277
[TBL] [Abstract][Full Text] [Related]
5. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma.
Bairey O; Blickstein D; Stark P; Prokocimer M; Nativ HM; Kirgner I; Shaklai M
Leuk Lymphoma; 2003 Oct; 44(10):1733-8. PubMed ID: 14692526
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations.
Tomita N; Kodama F; Sakai R; Koharasawa H; Hattori M; Taguchi J; Fujita H; Tanabe J; Fujisawa S; Fukawa H; Harano H; Kanamori H; Miyashita H; Matsuzaki M; Ogawa K; Motomura S; Maruta A; Ishigatsubo Y
Leuk Lymphoma; 2000 Jul; 38(3-4):335-43. PubMed ID: 10830740
[TBL] [Abstract][Full Text] [Related]
7. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
Bonnet C; Beguin Y; Fassotte MF; Seidel L; Luyckx F; Fillet G
Eur J Haematol; 2007 May; 78(5):399-404. PubMed ID: 17419741
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of the epithelial tumor marker CA-125 in non-Hodgkin's lymphoma.
Ozgüroglu M; Turna H; Demir G; Döventas A; Demirelli F; Mandel NM; Büyükünal E; Serdengeçti S; Berkarda B
Am J Clin Oncol; 1999 Dec; 22(6):615-8. PubMed ID: 10597748
[TBL] [Abstract][Full Text] [Related]
9. [Validity of the International Prognostic Index in non-Hodgkin's lymphomas of varying grades of malignancy].
Bettini R; Caronni F; Maino C; Marzetta K; Sala D; Saccà V; Gorini M
Recenti Prog Med; 2003 Nov; 94(11):494-500. PubMed ID: 14679917
[TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of serum lactate dehydrogenase, β2-microglobulin and vascular endothelial growth factor level detection in patients with non-Hodgkin's lymphoma].
Duan Y; Li G; Hu HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):608-10. PubMed ID: 22739165
[TBL] [Abstract][Full Text] [Related]
11. Value of serum beta 2 microglobulin as an indicator of early relapse in diffuse large cell lymphoma.
Avilés A; Narváez BR; Díaz-Maqueo JC; Guzmán R; Talavera A; García EL
Leuk Lymphoma; 1993 Mar; 9(4-5):377-80. PubMed ID: 7688627
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of serum CA125 levels in diffuse large B-cell lymphoma: potential role of a new sex- and age-adjusted reference value.
Gutiérrez A; Martínez-Serra J; Barceló B; Sampol A; Viñas L; González G; Bea MD; Amat JC; Martín J; Ramos R; Bautista A; Forteza-Rey J; Rodríguez J; Besalduch J
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):582-9. PubMed ID: 20201996
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma.
Cowan RA; Jones M; Harris M; Steward WP; Radford JA; Wagstaff J; Deakin DP; Crowther D
Br J Cancer; 1989 Feb; 59(2):276-82. PubMed ID: 2930692
[TBL] [Abstract][Full Text] [Related]
15. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
[TBL] [Abstract][Full Text] [Related]
16. Value of the determination of TNF-alpha in the plasma of patients with non-Hodgkins lymphoma.
Macia J; Gomez X; Esquerda A; Perez B; Callao V; Marzo C
Leuk Lymphoma; 1996 Feb; 20(5-6):481-6. PubMed ID: 8833407
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic value of pretreatment serum LDH in patients with limited disease small-cell lung carcinoma.
Stokkel MP; Van Eck-Smit BL; Zwinderman AH; Willems LN; Pauwels EK
Int J Biol Markers; 1997; 12(4):162-7. PubMed ID: 9582606
[TBL] [Abstract][Full Text] [Related]
18. Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma.
Doorduijn JK; Spruit P; van Der Holt B; van't Veer M; Budel L; Löwenberg B; Sonneveld P
Haematologica; 2000 Aug; 85(8):814-9. PubMed ID: 10942927
[TBL] [Abstract][Full Text] [Related]
19. Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
Pavlidis AN; Kalef-Ezra J; Bourantas LC; Lambrou A; Mavridis A
Int J Biol Markers; 1993; 8(1):14-20. PubMed ID: 8496627
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma: a single-centre experience.
Nachbaur D; Oberaigner W; Fritsch E; Nussbaumer W; Gastl G
Eur J Haematol; 2001 Jan; 66(1):43-9. PubMed ID: 11168507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]